Erdafitinib
Sign in to save this workspacePrimary targets: FGFR1 · FDA status: FDA Approved
Selectivity scorecard
KISS
95.71
Gini
0.737
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Erdafitinib. Strongest target: FGFR3 at 99.1% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR3 | 99.1% | 0.9% |
| 2 | FGFR2 | 99.0% | 1.0% |
| 3 | FGFR1 | 99.0% | 1.0% |
| 4 | FGFR4 | 98.0% | 2.0% |
| 5 | C_KIT | 98.0% | 2.0% |
| 6 | FLT4_VEGFR3 | 97.9% | 2.1% |
| 7 | LYN | 97.8% | 2.2% |
| 8 | FMS | 97.6% | 2.4% |
| 9 | EIF2AK2 | 97.0% | 3.0% |
| 10 | FLT1_VEGFR1 | 96.6% | 3.4% |
| 11 | DDR1 | 95.8% | 4.2% |
| 12 | RET | 94.7% | 5.3% |
| 13 | PDGFRA | 94.5% | 5.5% |
| 14 | DDR2 | 93.5% | 6.5% |
| 15 | KDR_VEGFR2 | 91.8% | 8.2% |
| 16 | LCK | 91.7% | 8.3% |
| 17 | ABL1 | 90.9% | 9.1% |
| 18 | EPHB4 | 89.7% | 10.3% |
| 19 | EPHB1 | 89.3% | 10.7% |
| 20 | EPHA5 | 87.6% | 12.4% |
Selectivity landscape
Where Erdafitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Erdafitinib.
Atlas insights for Erdafitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target4%
Off-target96%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2081.12 | |
| ALLOGRAFT_REJECTION | 7870.08 | |
| ANDROGEN_RESPONSE | 1104.34 | |
| ANGIOGENESIS | 1500.73 | |
| APICAL_JUNCTION | 8629.03 | |
| APICAL_SURFACE | 755.47 | |
| APOPTOSIS | 5552.60 | |
| BILE_ACID_METABOLISM | 664.98 | |
| CHOLESTEROL_HOMEOSTASIS | 1219.37 | |
| COAGULATION | 1086.87 | |
| COMPLEMENT | 4832.35 | |
| DNA_REPAIR | 1467.72 | |
| E2F_TARGETS | 3246.83 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1445.04 | |
| ESTROGEN_RESPONSE_EARLY | 2435.78 | |
| ESTROGEN_RESPONSE_LATE | 2227.32 | |
| FATTY_ACID_METABOLISM | 757.39 | |
| G2M_CHECKPOINT | 3605.79 | |
| GLYCOLYSIS | 2313.95 | |
| HEDGEHOG_SIGNALING | 760.93 | |
| HEME_METABOLISM | 1756.20 | |
| HYPOXIA | 3401.20 | |
| IL2_STAT5_SIGNALING | 2666.27 | |
| IL6_JAK_STAT3_SIGNALING | 4432.77 | |
| INFLAMMATORY_RESPONSE | 3739.22 | |
| INTERFERON_ALPHA_RESPONSE | 714.71 | |
| INTERFERON_GAMMA_RESPONSE | 5182.49 | |
| KRAS_SIGNALING_DN | 684.21 | |
| KRAS_SIGNALING_UP | 3098.51 | |
| MITOTIC_SPINDLE | 5691.66 | |
| MTORC1_SIGNALING | 3045.07 | |
| MYC_TARGETS_V1 | 2793.81 | |
| MYC_TARGETS_V2 | 636.40 | |
| MYOGENESIS | 2124.01 | |
| NOTCH_SIGNALING | 148.51 | |
| OXIDATIVE_PHOSPHORYLATION | 1325.75 | |
| P53_PATHWAY | 3005.31 | |
| PANCREAS_BETA_CELLS | 315.65 | |
| PEROXISOME | 858.26 | |
| PI3K_AKT_MTOR_SIGNALING | 8096.49 | |
| PROTEIN_SECRETION | 1700.36 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 464.38 | |
| SPERMATOGENESIS | 1048.79 | |
| TGF_BETA_SIGNALING | 1567.18 | |
| TNFA_SIGNALING_VIA_NFKB | 2943.40 | |
| UNFOLDED_PROTEIN_RESPONSE | 970.38 | |
| UV_RESPONSE_DN | 4245.22 | |
| UV_RESPONSE_UP | 2923.70 | |
| WNT_BETA_CATENIN_SIGNALING | 1382.80 | |
| XENOBIOTIC_METABOLISM | 1633.89 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.820 |
| EPT0291 | EPN | 0.818 |
| aMVAC.P_005_TURBT_S223 | — | 0.805 |
| SRR10899984 | — | 0.803 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.801 |
Annotations
Sign in to read and post annotations.
Loading…